Genesys Capital, founded in 2000, is a life science venture capital firm specializing in early-stage investments within the biotechnology, pharmaceuticals, and medical technology sectors. The firm typically participates in Series A and Series B funding rounds, with investment sizes ranging from $5 million to $15 million. Genesys Capital leverages its expertise and extensive network to accelerate the development of commercially viable healthcare startups.
Notable portfolio companies include Aptinyx, Invitae, and Veralox Therapeutics. Genesys Capital's investment philosophy focuses on identifying emerging bioscience opportunities and transforming them into successful commercial entities. The firm offers unique value-add services such as strategic guidance and access to a robust network of industry experts. Key partners at Genesys bring a wealth of experience from leading biotech firms and investment backgrounds, ensuring comprehensive support for their portfolio companies.
Genesys Capital - Portfolio Snapshot
Portfolio activity breakdown across disclosed investments and stages
